BACKGROUND: The source and outcomes of upper gastrointestinal bleeding (UGIB) in oncologic patients are poorly investigated. OBJECTIVE: The study aimed to investigate these issues in a tertiary academic referral center specialized in cancer treatment. METHODS: This was a retrospective study including all patients with cancer referred to endoscopy due to UGIB in 2010. RESULTS: UGIB was confirmed in 147 (of 324 patients) referred to endoscopy for a suspected episode of GI bleeding. Tumor was the most common cause of bleeding (N = 35, 23.8%), followed by varices (N = 30, 19.7%), peptic ulcer (N = 29, 16.3%) and gastroduodenal erosions (N = 16, 10.9%). Among the 32 patients with cancer of the upper GI tract, the main causes of bleeding were cancer (N = 27, 84.4%) and peptic ulcer (N = 5, 6.3%). Forty-one patients (27.9%) presented with bleeding from the primary tumor or from a metastatic lesion, and seven received endoscopic therapy, with successful initial hemostasis in six (85.7%). Rebleeding and mortality rates were not different between endoscopically treated (N = 7) and non-treated (N = 34) patients (28.6% vs. 14.7%, p = 0.342; 43.9% vs. 44.1%, p = 0.677). Median survival was 20 days, and the overall 30-day mortality rate was 44.9%. There was no predictive factor of mortality or rebleeding. CONCLUSION: Tumor bleeding is the most common cause of UGIB in cancer patients. UGIB in cancer patients correlates with a high mortality rate regardless of the bleeding source. Current endoscopic treatments may not be effective in preventing rebleeding or improving survival.
BACKGROUND: The source and outcomes of upper gastrointestinal bleeding (UGIB) in oncologic patients are poorly investigated. OBJECTIVE: The study aimed to investigate these issues in a tertiary academic referral center specialized in cancer treatment. METHODS: This was a retrospective study including all patients with cancer referred to endoscopy due to UGIB in 2010. RESULTS: UGIB was confirmed in 147 (of 324 patients) referred to endoscopy for a suspected episode of GI bleeding. Tumor was the most common cause of bleeding (N = 35, 23.8%), followed by varices (N = 30, 19.7%), peptic ulcer (N = 29, 16.3%) and gastroduodenal erosions (N = 16, 10.9%). Among the 32 patients with cancer of the upper GI tract, the main causes of bleeding were cancer (N = 27, 84.4%) and peptic ulcer (N = 5, 6.3%). Forty-one patients (27.9%) presented with bleeding from the primary tumor or from a metastatic lesion, and seven received endoscopic therapy, with successful initial hemostasis in six (85.7%). Rebleeding and mortality rates were not different between endoscopically treated (N = 7) and non-treated (N = 34) patients (28.6% vs. 14.7%, p = 0.342; 43.9% vs. 44.1%, p = 0.677). Median survival was 20 days, and the overall 30-day mortality rate was 44.9%. There was no predictive factor of mortality or rebleeding. CONCLUSION:Tumor bleeding is the most common cause of UGIB in cancerpatients. UGIB in cancerpatients correlates with a high mortality rate regardless of the bleeding source. Current endoscopic treatments may not be effective in preventing rebleeding or improving survival.
Authors: Stephen J Heller; Jeffrey L Tokar; Minhhuyen T Nguyen; Oleh Haluszka; David S Weinberg Journal: Gastrointest Endosc Date: 2010-10 Impact factor: 9.427
Authors: Joseph J Y Sung; Kelvin K F Tsoi; Terry K W Ma; Man-Yee Yung; James Y W Lau; Philip W Y Chiu Journal: Am J Gastroenterol Date: 2009-09-15 Impact factor: 10.864
Authors: T J Savides; D M Jensen; J Cohen; G M Randall; T O Kovacs; E Pelayo; S Cheng; M E Jensen; H Y Hsieh Journal: Endoscopy Date: 1996-02 Impact factor: 10.093